Income Statement
DERMATA THERAPEUTICS, INC.
DRMA
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
- | - | - | - | - |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
- | - | - | - | - |
|
Operating Expenses
|
7.77 | 12.51 | 8.04 | 9.67 | 7.86 |
|
Research & Development
|
2.93 | 8.20 | 4.07 | 5.65 | 3.46 |
|
Selling, General & Administrative
|
4.84 | 4.31 | 3.97 | 4.02 | 4.40 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-7.77 | -12.51 | -8.04 | -9.67 | -7.86 |
|
Non-Operating Income
|
- | - | - | - | - |
|
Interest Income
|
0.22 | 0.23 | 0.25 | - | - |
|
Interest Expense
|
- | - | - | - | 0.05 |
|
Other Non-Op Income / Expense
|
- | - | - | - | - |
|
Income Before Tax
|
- | - | - | - | - |
|
Income Tax Expense
|
- | - | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-7.56 | -12.29 | -7.79 | -9.61 | -7.90 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-7.77 | -12.51 | -8.04 | -9.67 | -7.86 |
|
Earnings Per Share (Basic)
|
-8.16 | -8.03 | -2.67 | -0.87 | -2.43 |
|
Diluted EPS
|
-8.16 | -8.03 | - | - | - |
|
Weighted Average Shares
|
0.93 | - | - | 11.05 | 4.30 |
|
Diluted Weighted Avg Shares
|
0.93 | 1.53 | - | - | - |
|
Comprehensive Income
|
- | - | - | 0.00 | - |